Revvity, Inc. (PKN.F)

99,86 +1,54 (+1,57%) Alla chiusura: 03:52PM CEST

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 11.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Prahlad R. Singh Ph.D.	CEO, President & Director	1,32M	N/D	1965
Mr. Maxwell Krakowiak	Senior VP & CFO	580,74k	N/D	1990
Mr. Tajinder S. Vohra	Senior Vice President of Global Operations	528,25k	N/D	1966
Mr. Joel S. Goldberg	Senior VP of Administration, General Counsel & Secretary	663,22k	N/D	1969
Ms. Miriame Victor	Senior VP & Chief Commercial Officer	511,07k	N/D	1982
Mr. Andrew Okun	VP, Chief Accounting Officer & Treasurer	N/D	N/D	1970
Ms. Madhuri Hegde FACMG, Ph.D.	Senior VP & Chief Scientific Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Revvity, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 3; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.